Why does the NHS use lower BMI cut-offs for some ethnic groups?
NICE uses 27.5, not 30, as the obesity line for several ethnic groups. NHS thresholds for Mounjaro and Wegovy drop to match. Here is the evidence, and its limits.
Written for the UK. Reading from India? India version
Because type 2 diabetes and heart risk rise at a lower BMI in some groups. NICE uses 27.5, not 30, as the obesity line for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean background. The same 2.5-point cut applies to NHS thresholds for weight medicines such as Mounjaro and Wegovy.
Key takeaways
- NICE treats a BMI of 27.5 or more as obesity for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean background, instead of 30.1
- A study of 1.47 million English GP records found South Asian adults at BMI 23.9 had the diabetes risk of White adults at BMI 30.2
- NICE lowers NHS BMI thresholds for Mounjaro and Wegovy by 2.5 points for the same groups, so a cut-off of 35 becomes 32.5.3,4
- The UK licences for Mounjaro and Wegovy are written without an ethnicity adjustment: a BMI of 30, or 27 with a weight-related condition.5,6
- NICE also uses waist-to-height ratio for anyone with a BMI under 35: 0.5 to 0.59 means increased risk, and 0.6 or more means high risk.1
- GLP‑1 medicines are prescription-only medicines in the UK, never sold over the counter.7
- Ozempic and Rybelsus are licensed for type 2 diabetes only, not for weight loss.8
- A prescriber decides whether a medicine fits, which one and at what dose. Nothing here is a recommendation.
- The risks are the same however you get it: see our side effects guide.
On this page
What are the NICE BMI cut-offs?
For most adults, overweight starts at 25 and obesity at 30; for the groups NICE names, overweight starts at 23 and obesity at 27.5.1
BMI (body mass index) is your weight in kilograms divided by your height in metres, squared. NICE’s obesity guideline sets these bands:1
| Band | Most adults | Named ethnic groups |
|---|---|---|
| Overweight | 25 to 29.9 | 23 to 27.4 |
| Obesity | 30 or more | 27.5 or more |
| Obesity class 3 | 40 or more | 37.5 or more |
Named groups: South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean background. NICE lowers the class 2 and 3 thresholds by 2.5. Source: NICE NG246, recommendations 1.9.10 and 1.9.11.1
For someone 1.70 m (5 ft 7 in) tall, BMI 30 is about 87 kg (13 st 9 lb). BMI 27.5 is about 79 kg (12 st 7 lb). That gap of about 7 kg (1 st 2 lb) is what the lower line means in practice.
Why does the same BMI mean more risk for some groups?
Because many people in these groups carry more fat around the middle, and their diabetes and heart risk rises at a lower BMI.1,2
NICE says people in these groups “are prone to central adiposity”, meaning fat around the belly and organs. Their “cardiometabolic risk occurs at lower BMI”.1
The clearest English evidence is a 2021 study of 1,472,819 adults in GP records. It followed them for a median of 6.5 years.2 It asked which BMI gave the same type 2 diabetes risk as a BMI of 30 in White adults:2
So the risk gap varies a lot between groups. NICE still uses one practical figure, 27.5, for all of them.1
How does ethnicity change NHS rules for weight medicines?
On the NHS, NICE lowers each BMI threshold for Mounjaro and Wegovy by 2.5 for these groups, so 35 becomes 32.5 and 40 becomes 37.5.3,4
Mounjaro, England. NICE gives the example of 37.5 instead of 40 in the current phases.3 The phase from around June 2026 covers BMI 32.5 to 37.4 with 4 of 5 named conditions for these groups. See Mounjaro on the NHS.
Wegovy, England. NICE’s usual 35 becomes 32.5, and its 30 to 34.9 band becomes 27.5 to 32.4.4 Scotland’s SMC says a lower cut-off “may be more appropriate” for minority ethnic groups.9
Private prescriptions follow the medicine’s licence. The licence wording for both is a BMI of 30, or 27 with a weight-related condition. No ethnicity adjustment is written in.5,6
Uses the NICE cut-offs, including the lower ones for some ethnic groups. No sign-up.
What does waist-to-height ratio add?
It measures belly fat directly: NICE says a ratio of 0.5 to 0.59 means increased health risk, and 0.6 or more means high risk.1
NICE uses it for adults with a BMI under 35, of both sexes and all ethnicities.1 It also tells clinicians that someone with a “healthy” BMI may still carry too much central fat.1
To measure, find the bottom of your ribs and the top of your hips. Measure around your waist midway between them, just above the belly button, after breathing out.10
Then divide your waist by your height, in the same units. NICE’s example: 96.5 cm ÷ 170 cm = 0.57, or 38 in ÷ 67 in = 0.57.1,10 Our guide to weight and health explains both measures.
What are the limits of these cut-offs?
They are a practical shortcut, not a diagnosis: one figure covers very different groups, and NICE itself lists open research questions.2,11
The English study found equivalent points from 23.9 to 28.1 depending on group.2 NICE’s single 27.5 line sits between them.1
NICE asks researchers whether the same thresholds hold for first-, second- and third-generation immigrants.11 We found no NICE guidance on how to apply the thresholds to people of mixed heritage. The study used self-reported ethnicity.2
A threshold is the beginning of a conversation with a clinician, not a verdict. Our guide on whether to consider a GLP‑1 covers the rest of that decision.
Questions people ask
Is the BMI cut-off lower for South Asians in the UK?
Yes. For people of South Asian background, NICE treats BMI 23 to 27.4 as overweight and 27.5 or more as obesity. Several other groups share these cut-offs.1
Does the lower BMI apply to Mounjaro on the NHS?
Yes. NICE lowers the qualifying BMIs by 2.5 for the named groups, for example 37.5 instead of 40.3
Does it apply to private prescriptions?
The licence wording sets a BMI of 30, or 27 with a weight-related condition, without an ethnicity adjustment. A private prescriber must still verify your weight and history independently.5,6,12
Which groups does NICE name?
South Asian, Chinese, other Asian, Middle Eastern, Black African and African-Caribbean backgrounds.1
Is waist-to-height ratio better than BMI?
NICE uses both. BMI classifies weight, and waist-to-height ratio shows central fat in people with a BMI under 35, whatever their ethnicity.1
How we researched this
On 12 October 2026 we read NICE NG246 (recommendations 1.9.10–1.9.14, Box 1 and research recommendations), TA1026 and TA875. We also read the SMC decision and the Caleyachetty 2021 study abstract.
Stone and pound conversions are our arithmetic. NICE’s thresholds come from guidance; the study figures come from one large English cohort.
Before you move on
- Work out your BMI and check it against the band for your background.
- Measure your waist-to-height ratio if your BMI is under 35.
- Know that NHS medicine thresholds are 2.5 lower for the named groups.
- Tell your GP your ethnic background if it isn’t on your record.
- Treat any threshold as the beginning of a conversation, not a decision.
More from the UK blog
The monthly UK update
An independent guide to GLP‑1 medicines. We don’t sell medicines, take drug-company money, earn commissions or link to any provider. Once a month: NHS changes, approvals, list prices and safety alerts. How we write
Sources
- NICE. Overweight and obesity management, guideline NG246, section 1.9: identifying and assessing overweight, obesity and central adiposity. Published 14 January 2025, last updated 8 January 2026. Link
- Caleyachetty R et al. Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study. Lancet Diabetes Endocrinol 2021;9:419–26. PMID 33989535. Link
- NICE. Tirzepatide for managing overweight and obesity, technology appraisal TA1026, section 1 (recommendations and “What this means in practice”). Published 23 December 2024, last updated 1 September 2025. Link
- NICE. Semaglutide for managing overweight and obesity, technology appraisal TA875, section 1. Published 8 March 2023, last updated 4 September 2023. Link
- NICE. TA1026, section 2: Information about tirzepatide (marketing authorisation, list prices excluding VAT, commercial arrangement). Link
- NICE. TA875, section 2: Information about semaglutide (list prices excluding VAT, 2023). Link
- MHRA. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes. Press release, 10 August 2026. Link
- MHRA. GLP-1 medicines for weight loss and diabetes: what you need to know. Guidance, published 5 June 2025, updated 5 February 2026. Link
- Scottish Medicines Consortium. Tirzepatide (Mounjaro) for obesity, SMC2653: accepted for restricted use within NHSScotland. Link
- NICE. NG246, Box 1: method for people to measure their own waist and calculate their waist-to-height ratio. Link
- NICE. NG246, recommendations for research (21: comparative risks for different generations of immigrants). Link
- General Pharmaceutical Council. Providing weight management services: FAQs. Link
Last checked 12 Oct 2026 · Next review due 12 Apr 2027 · Report an error
How this post was made. Written by the GLP Guidebook team from the sources above. It’s general information, not medical advice. Talk to your GP, pharmacist or prescriber before starting, stopping or changing any medicine. We don’t sell, prescribe or recommend any brand or provider. How we write